{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,28]],"date-time":"2026-04-28T23:53:05Z","timestamp":1777420385484,"version":"3.51.4"},"reference-count":25,"publisher":"SAGE Publications","issue":"11","license":[{"start":{"date-parts":[[2025,3,15]],"date-time":"2025-03-15T00:00:00Z","timestamp":1741996800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.sagepub.com\/page\/policies\/text-and-data-mining-license"}],"content-domain":{"domain":["journals.sagepub.com"],"crossmark-restriction":true},"short-container-title":["Ann Pharmacother"],"published-print":{"date-parts":[[2025,11]]},"abstract":"<jats:sec>\n                    <jats:title>Background:<\/jats:title>\n                    <jats:p>Serotonin reuptake inhibitor (SRI) antidepressants have known antiplatelet properties. Patients with hematologic malignancies (HMs) are at an increased risk of bleeding complications due to their malignancy and treatment-induced thrombocytopenia.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Objective:<\/jats:title>\n                    <jats:p>The purpose of this study was to evaluate the risk of clinically significant bleeding (CSB) in patients with HM and thrombocytopenia who are prescribed SRIs.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods:<\/jats:title>\n                    <jats:p>This retrospective cohort study included adult patients admitted to the hospital with HM and thrombocytopenia. Patients were stratified into SRI-exposed and SRI-unexposed groups. Patients were followed up until resolution of thrombocytopenia, hospital discharge, death, or SRI therapy interruption. The primary outcome was the incidence of CSB.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results:<\/jats:title>\n                    <jats:p>\n                      A total of the 324 patients were included in the study (119 SRI exposed vs 205 SRI unexposed). The median baseline platelet value was 35 \u00d7 10\n                      <jats:sup>9<\/jats:sup>\n                      \/L and 31 \u00d7 10\n                      <jats:sup>9<\/jats:sup>\n                      \/L, respectively. The median platelet nadir was 6 \u00d7 10\n                      <jats:sup>9<\/jats:sup>\n                      \/L, and the median duration of study inclusion was 12 days in both groups. No difference was seen in the incidence of CSB between groups (16% vs 13%,\n                      <jats:italic>P<\/jats:italic>\n                      = 0.487). Hospital length of stay (LOS) (20 vs 19 days,\n                      <jats:italic>P<\/jats:italic>\n                      = 0.227) and intensive care unit (ICU) LOS (3.9 vs 3.9 days,\n                      <jats:italic>P<\/jats:italic>\n                      = 0.996) were similar between groups. On multivariable analysis, SRI exposure was not independently associated with CSB (adjusted odds ratio [aOR] = 1.46, 95% confidence interval [CI] 0.75-2.86).\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion and Relevance:<\/jats:title>\n                    <jats:p>In patients with HM and thrombocytopenia, SRI exposure was not associated with an increased risk of CSB. Given the small study size, assessment of patient-specific risks versus benefits should still be considered when prescribing SRI therapy in this patient population.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1177\/10600280251319757","type":"journal-article","created":{"date-parts":[[2025,3,15]],"date-time":"2025-03-15T07:08:06Z","timestamp":1742022486000},"page":"989-998","update-policy":"https:\/\/doi.org\/10.1177\/sage-journals-update-policy","source":"Crossref","is-referenced-by-count":0,"title":["Serotonergic Antidepressant Use and Risk of Clinically Significant Bleeding in Thrombocytopenic Hematologic Malignancy Patients"],"prefix":"10.1177","volume":"59","author":[{"ORCID":"https:\/\/orcid.org\/0009-0004-9080-7074","authenticated-orcid":false,"given":"Hannah","family":"Delp","sequence":"first","affiliation":[{"name":"Department of Pharmacy, Barnes-Jewish Hospital, St. Louis, MO, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marissa","family":"Olson","sequence":"additional","affiliation":[{"name":"Department of Pharmacy, Barnes-Jewish Hospital, St. Louis, MO, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Emily","family":"Owen","sequence":"additional","affiliation":[{"name":"Department of Pharmacy, Barnes-Jewish Hospital, St. Louis, MO, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Colleen","family":"McEvoy","sequence":"additional","affiliation":[{"name":"Division of Pulmonary and Critical Care Medicine, Department of Medicine, School of Medicine, Washington University, St. Louis, MO, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3504-2070","authenticated-orcid":false,"given":"Emily","family":"Gill","sequence":"additional","affiliation":[{"name":"Department of Pharmacy, Barnes-Jewish Hospital, St. Louis, MO, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"179","published-online":{"date-parts":[[2025,3,15]]},"reference":[{"key":"e_1_3_2_2_2","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD011006.pub4"},{"key":"e_1_3_2_3_2","doi-asserted-by":"publisher","DOI":"10.3389\/fpubh.2022.1000000"},{"key":"e_1_3_2_4_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2003.08.025"},{"key":"e_1_3_2_5_2","doi-asserted-by":"publisher","DOI":"10.1002\/(SICI)1099-1611(199807\/08)7:4<291::AID-PON361>3.0.CO;2-U"},{"key":"e_1_3_2_6_2","doi-asserted-by":"publisher","DOI":"10.1159\/000366551"},{"key":"e_1_3_2_7_2","doi-asserted-by":"publisher","DOI":"10.1038\/clpt.2010.240"},{"key":"e_1_3_2_8_2","doi-asserted-by":"publisher","DOI":"10.1001\/jamaneurol.2016.4529"},{"key":"e_1_3_2_9_2","doi-asserted-by":"publisher","DOI":"10.4088\/JCP.09r05786blu"},{"key":"e_1_3_2_10_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.cgh.2014.06.021"},{"key":"e_1_3_2_11_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.beha.2022.101353"},{"key":"e_1_3_2_12_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1212772"},{"key":"e_1_3_2_13_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.1997.15.3.1143"},{"key":"e_1_3_2_14_2","doi-asserted-by":"publisher","DOI":"10.1053\/bbmt.2002.v8.pm12434952"},{"key":"e_1_3_2_15_2","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.22434"},{"key":"e_1_3_2_16_2","doi-asserted-by":"publisher","DOI":"10.1186\/s12872-022-02557-1"},{"key":"e_1_3_2_17_2","doi-asserted-by":"publisher","DOI":"10.1038\/ajg.2009.128"},{"key":"e_1_3_2_18_2","doi-asserted-by":"publisher","DOI":"10.1001\/archinte.164.21.2367"},{"key":"e_1_3_2_19_2","doi-asserted-by":"publisher","DOI":"10.1002\/phar.2632"},{"key":"e_1_3_2_20_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM199402103300601"},{"key":"e_1_3_2_21_2","doi-asserted-by":"publisher","DOI":"10.1176\/appi.ajp.2013.12111467"},{"key":"e_1_3_2_22_2","doi-asserted-by":"publisher","DOI":"10.1001\/jamanetworkopen.2024.3208"},{"key":"e_1_3_2_23_2","doi-asserted-by":"publisher","DOI":"10.1001\/archpsyc.65.7.795"},{"key":"e_1_3_2_24_2","volume-title":"Defitelio (defibrotide) [package insert]","author":"Jazz Pharmaceuticals Inc","year":"2022","unstructured":"Jazz Pharmaceuticals Inc. Defitelio (defibrotide) [package insert]. Jazz Pharmaceuticals Inc.; 2022."},{"key":"e_1_3_2_25_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.clml.2018.06.016"},{"key":"e_1_3_2_26_2","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.12948"}],"container-title":["Annals of Pharmacotherapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/10600280251319757","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/full-xml\/10.1177\/10600280251319757","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/10600280251319757","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,28]],"date-time":"2026-04-28T11:14:01Z","timestamp":1777374841000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.sagepub.com\/doi\/10.1177\/10600280251319757"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,3,15]]},"references-count":25,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2025,11]]}},"alternative-id":["10.1177\/10600280251319757"],"URL":"https:\/\/doi.org\/10.1177\/10600280251319757","relation":{},"ISSN":["1060-0280","1542-6270"],"issn-type":[{"value":"1060-0280","type":"print"},{"value":"1542-6270","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,3,15]]}}}